Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial

authors

• Graillon Thomas
• Sanson Marc
• Campello Chantal
• Idbaih Ahmed
• Peyre Matthieu
• Peyrière Hadrien
• Basset Noémie
• Autran Didier
• Kalamarides Michel
• Roche Pierre-Hugues
• Fuentes Stéphane
• Tabouret Emeline
• Barrie Maryline
• Cohen Anita
• Honoré Stéphane
• Boucekine Mohamed
• Baumstarck Karine
• Figarella‑branger Dominique
• Barlier Anne A.
• Dufour Henry
• Chinot Olivier Louis

document type

abstract

Aggressive meningiomas that progress after surgery/radiotherapy represent an unmet medical need. Strong and constant expression of SSTR2A receptors and activation of the Pi3K/Akt/mTOR pathway have been demonstrated in meningiomas. The combination of everolimus, an mTOR inhibitor, and octreotide, a somatostatin agonist, has shown additive antitumor effect in vitro. The phase II CEVOREM trial investigated the efficacy of this combination on recurrent meningiomas.

more information